Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Ketteler

Showing results (101-110 of 220) with videos related to

Pageof 22
Sort By:
Nephron|June 26, 2020
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 StudyAdrian C Covic, Stuart M Sprague, Anjay Rastogi, et al.
Circulation|May 9, 2007
Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul StudyJoachim H Ix, Glenn M Chertow, Michael G Shlipak, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 31, 2002
Development of lumbar bone mineral density in the late course after kidney transplantationVincent M Brandenburg, Markus Ketteler, Walter J Fassbender, et al.
Kidney International Reports|March 18, 2021
Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical TrialMarkus Ketteler, Andrzej Wiecek, Alexander R Rosenkranz, et al.
American Journal of Nephrology|July 20, 2016
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis PatientsStuart M Sprague, Adrian C Covic, Jürgen Floege, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 28, 2002
Bone pain with scintigraphy suggestive of widespread metastases--do not forget phosphateVincent M Brandenburg, Markus Ketteler, Rolf D Frank, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 29, 2006
Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul StudyJoachim H Ix, Glenn M Chertow, Michael G Shlipak, et al.
Advances in Therapy|March 11, 2021
Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort StudyMarkus Ketteler, Kristina Chen, Elvira O Gosmanova, et al.
Journal of the American Society of Nephrology : JASN|September 24, 2005
Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient miceMarc W Merx, Cora Schäfer, Ralf Westenfeld, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 31, 2018
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patientsMarkus Ketteler, Stuart M Sprague, Adrian C Covic, et al.
Pageof 22

Showing results (101-110 of 220) with videos related to

Sort By:
Pageof 22
Nephron|June 26, 2020
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 StudyAdrian C Covic, Stuart M Sprague, Anjay Rastogi, et al.
Circulation|May 9, 2007
Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul StudyJoachim H Ix, Glenn M Chertow, Michael G Shlipak, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 31, 2002
Development of lumbar bone mineral density in the late course after kidney transplantationVincent M Brandenburg, Markus Ketteler, Walter J Fassbender, et al.
Kidney International Reports|March 18, 2021
Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical TrialMarkus Ketteler, Andrzej Wiecek, Alexander R Rosenkranz, et al.
American Journal of Nephrology|July 20, 2016
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis PatientsStuart M Sprague, Adrian C Covic, Jürgen Floege, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 28, 2002
Bone pain with scintigraphy suggestive of widespread metastases--do not forget phosphateVincent M Brandenburg, Markus Ketteler, Rolf D Frank, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 29, 2006
Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul StudyJoachim H Ix, Glenn M Chertow, Michael G Shlipak, et al.
Advances in Therapy|March 11, 2021
Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort StudyMarkus Ketteler, Kristina Chen, Elvira O Gosmanova, et al.
Journal of the American Society of Nephrology : JASN|September 24, 2005
Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient miceMarc W Merx, Cora Schäfer, Ralf Westenfeld, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 31, 2018
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patientsMarkus Ketteler, Stuart M Sprague, Adrian C Covic, et al.
Pageof 22